News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
US approval for hepatitis C drug telaprevir

The US Food and Drug Administration has approved a new hepatitis C drug telaprevir (Incivek), the agency announced today. Telaprevir is a direct-acting antiviral drug (an HCV protease inhibitor),

Published
23 May 2011
By
Keith Alcorn
New and experimental hepatitis C treatment
European approval recommended for hepatitis C drug boceprevir

The European Medicines Agency has recommended marketing approval for Merck’s hepatitis C protease inhibitor boceprevir (Victrelis), the agency announced on May 20th. Boceprevir is the first direct-acting antiviral

Published
23 May 2011
By
Keith Alcorn
New and experimental hepatitis C treatment
European approval for new hepatitis C drug boceprevir (Victrelis)

On 19 May 2011 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Victrelis 200 mg hard capsules intended for the treatment of chronic hepatitis C (CHC).

Published
20 May 2011
From
European Medicines Agency
New and experimental hepatitis C treatment
The Fair Pricing Coalition Expresses Dismay at the Price of Merck's Newly Approved Hepatitis C Drug

"While this new drug approval is a very exciting development for the HCV community, the Fair Pricing Coalition (FPC) is very disappointed at the price set by Merck for Victrelis," said Fair Pricing Coalition member Lynda Dee.

Published
18 May 2011
From
Thebody.com
New and experimental hepatitis C treatment
Merck, Roche to Work Together on Hepatitis C Treatments

Roche Holding AG and Merck & Co. will work together to market treatments for hepatitis C in the U.S., promoting Merck's new boceprevir with an older drug from Roche in a market estimated to reach $15 billion annually by 2019.

Published
18 May 2011
From
San Francisco Chronicle
New and experimental hepatitis C treatment
Getting Ready; Telaprevir or Boceprevir ?

I can't help but wonder if  hepatitis C patients who are preparing to treat are ready to choose between the two new drugs; Telaprevir "INCIVEK" or Boceprevir "VICTRELIS". More importantly I wonder if patients understand the dire need for an experienced physician to be on board for this complicated  three drug regimen of difficult to tolerate drugs (maybe more including rescue drugs) which will involve treating for 24 to 48 weeks.

Published
18 May 2011
From
HCV New Drugs Research
New and experimental hepatitis C treatment
Merck’s Hepatitis C Drug Wins F.D.A. Approval

The Food and Drug Administration approved on Friday the first of a new generation of hepatitis C drugs that promises to increase the cure rate while shortening the time required for treatment.

Published
16 May 2011
From
New York Times
New and experimental hepatitis C treatment
Vertex hepatitis C drug gets glowing endorsement

The Food and Drug Administration committee voted 18-0 on Thursday to recommend approval of telaprevir, one of two new proposed medicines offering higher cure rates and often shorter treatment for a virus that can destroy the liver.

Published
29 April 2011
From
Reuters
New and experimental hepatitis C treatment
US FDA panel backs Merck hepatitis drug

The Merck & Co hepatitis C drug boceprevir moved closer to the market on Wednesday as U.S. advisers unanimously urged approval and called it a major advance against a hard-to-treat disease.

Published
28 April 2011
From
Reuters
New and experimental hepatitis C treatment
Some Biotechs May Benefit From Hepatitis C Treatment Market Shift

Annual US sales of telaprevir and boceprevir have bene estimated at $2.6 to $4.2 billion over the next five years, and up to 650,000 patients with hepatitis C may be awaiting treatment in the US alone.

Published
27 April 2011
From
Seeking Alpha
← Prev1...5960616263...65Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.